Can mCPN Intervention Improve Injection Site Rotation

NCT ID: NCT03914183

Last Updated: 2019-04-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

209 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-15

Study Completion Date

2019-04-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current research study has accordingly been designed to determine if a "pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention" will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design and Conduct This is a 30-day, two-arm, randomized, controlled study.

Enrolled participants will be randomly assigned to one of the following study arms:

* Control group: participating pharmacists will dispense boxes of standard insulin pen needles to the patient participants
* mCPN group: participating pharmacists will dispense boxes of montméd Coloured Pen Needles to the patient participants

Study Sites and Participating Pharmacists All pharmacies in Canada that provide services to individuals with diabetes who use injectable insulin therapy will be eligible to participate in this study. All participating pharmacists who will play an active role in participant enrollment and the follow-up visits will be required to complete a participation consent form and 2 surveys. The first (Pre-study survey) should be completed after they have been fully trained on the study protocol and their study obligations, and before commencement of study enrollment. The second (Post-study survey) should be completed after the last patient has completed the 30-day follow-up visit. (Refer to Section 11 for the Study Flow).

Randomization Process Participating pharmacists will dispense one of the two study pen needles according to a computer-generated list that will be provided to the participating pharmacy upon site activation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Injection Site Rotation Diabete Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Open label randomized control study of control (current standard of care) versus mCPN intervention
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Standard of care arm - using insulin pen needles as previously prescribed

Group Type OTHER

Control

Intervention Type DEVICE

Use of standard of care insulin pen needle

mCPN intervention

Each box of montméd Coloured Pen Needles (mCPN) has the following five features:

i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message "Change color, change site" siteTM" iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened The current research study has accordingly been designed to determine if a "pharmacist-dispensed montméd Coloured Pen Needle (mCPN) intervention" will improve injection site rotation relative to the standard dispensing of non-mCPN insulin pen needles.

Group Type ACTIVE_COMPARATOR

mCPN Intervention

Intervention Type DEVICE

Each box of montméd Coloured Pen Needles (mCPN) has the following five features:

i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message "Change color, change site" siteTM" iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mCPN Intervention

Each box of montméd Coloured Pen Needles (mCPN) has the following five features:

i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message "Change color, change site" siteTM" iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened

Intervention Type DEVICE

Control

Use of standard of care insulin pen needle

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 diabetes mellitus or type 2 diabetes mellitus who have been using daily insulin therapy for 1 year or more
* Able to read the English text on the boxes of the pen needles

Exclusion Criteria

* Individuals currently treated with a glucagon-like peptide 1 receptor agonist (GLP-1RA)
* Current or previous user of mCPN
* Individuals who are unable to understand or communicate in English
* Pregnant women
* Individuals with serious mental illnesses eg. dementia, schizophrenia disorders, bipolar disorders, major depression, etc.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Montméd

UNKNOWN

Sponsor Role collaborator

Pink Pearls Inc

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lori Berard

Nurse Consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lori Berard

Role: PRINCIPAL_INVESTIGATOR

Pink Pearls Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shoppers Drug Mart 2335

Calgary, Alberta, Canada

Site Status

Claresholm Pharamcy

Claresholm, Alberta, Canada

Site Status

Rexall 7236

Edmonton, Alberta, Canada

Site Status

Shoppers Drug Mart 2401

Okotoks, Alberta, Canada

Site Status

Kipp Mallery Pharmacy

Kamloops, British Columbia, Canada

Site Status

Our Own Health Centre

Winnipeg, Manitoba, Canada

Site Status

Shoppers Drug Mart 535

Winnipeg, Manitoba, Canada

Site Status

Kennegecasis Drugs

Rothesay, New Brunswick, Canada

Site Status

Zak's Pharmacy

Milton, Ontario, Canada

Site Status

Niagara Pharmacy

Niagara Falls, Ontario, Canada

Site Status

Northgate Pharmacy

Sarnia, Ontario, Canada

Site Status

Murphy's Cornwall Pharmacy

Cornwall, Prince Edward Island, Canada

Site Status

Pharmacie Jacques Bourget PJC076

Laval, Quebec, Canada

Site Status

Pharmacy Jean-Coutu Raffaele Delli Colli & Gino Consolante

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

mCPN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluating the InPen in Pediatric Type 1 Diabetes
NCT05515939 ACTIVE_NOT_RECRUITING
Smart MDI Study (CIP343)
NCT06645834 COMPLETED NA
Dose Response Study of Transdermal Human Insulin in Patients
NCT05159453 NOT_YET_RECRUITING PHASE2/PHASE3
Connected Pens for Diabetes Study
NCT03830216 TERMINATED NA
An Adaptive Design Study of MTX228
NCT06474598 RECRUITING PHASE2
New Glucose Sensor Pediatric
NCT01161043 COMPLETED NA
CEP249 Pediatric Accuracy Study
NCT01991470 COMPLETED NA